Exelixis, Inc. (EXEL) Discusses Strategic Approach to Building Next-Generation Oncology Franchises at R&D Day Transcript

Exelixis, Inc. (EXEL) Discusses Strategic Approach to Building Next-Generation Oncology Franchises at R&D Day Transcript

Seeking Alpha • Dec 11, 2025

Why Is Exelixis (EXEL) Up 9% Since Last Earnings Report?

Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Dec 4, 2025

Exelixis to Webcast Virtual 2025 Research & Development (R&D) Day on Wednesday, December 10, 2025

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that it will webcast its virtual event, Exelixis 2025 R&D Day: Building Next-generation Oncology Franchises, on Wednesday, December 10, 2025, from 1:00 p.m. to 3:30 p.m. EST. During the event, featured speakers will review the progress of Exelixis' R&D activities and outline the company's strategy to advance future oncology franchises. These efforts underscore Exelixis' continued focus on raising standards o.

Business Wire • Dec 3, 2025

2 Under-the-Radar Stocks to Buy Heading Into 2026

Axsome Therapeutics boasts a deep late-stage pipeline with billions in potential revenue opportunity. Exelixis' core franchise remains strong while it develops promising new medicines.

The Motley Fool • Dec 2, 2025

Here's Why Exelixis (EXEL) is a Strong Growth Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Investment Research • Nov 28, 2025

Why Exelixis (EXEL) International Revenue Trends Deserve Your Attention

Evaluate Exelixis' (EXEL) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.

Zacks Investment Research • Nov 17, 2025

Here's Why Exelixis (EXEL) is a Strong Momentum Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Investment Research • Nov 13, 2025

Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Investment Research • Nov 11, 2025

Exelixis, Inc. (EXEL) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference Transcript

Exelixis, Inc. ( EXEL ) Guggenheim Securities 2nd Annual Healthcare Innovation Conference November 10, 2025 10:30 AM EST Company Participants Michael Morrissey - CEO, President & Director Conference Call Participants Michael Schmidt - Guggenheim Securities, LLC, Research Division Presentation Michael Schmidt Guggenheim Securities, LLC, Research Division Welcome to this next fireside chat with Exelixis. With us today, we have Mike Morrissey, President and CEO.

Seeking Alpha • Nov 10, 2025

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in November: Guggenheim 2nd Annual Healthcare Innovation Conference: Exelixis is scheduled to present at 10:30 a.m. ET / 7:30 a.m. PT on Monday, November 10 in Boston. Stifel 2025 Healthcare Conference: Exelixis is scheduled to present at 8:40 a.m. ET / 5:40 a.m. PT on Tuesday, November 11 in New York City. To access the.

Business Wire • Nov 6, 2025